Dual‐Targeted Therapy in Cardiometabolic Risk: A Meta‐Analysis of Telmisartan‐Based Combinations for Hypertension and Dyslipidemia
Telmisartan + amlodipine demonstrates superior antihypertensive efficacy, while telmisartan + rosuvastatin more effectively lowers LDL-C. Safety profiles are comparable. Findings support the selection of a regimen based on individualized therapeutic goals.
Authors
- Sowjanya Kapaganti (ORCID: https://orcid.org/0009-0004-4323-9502)
- Binish Qureshi
- Harigopal Sandhyavenu
- Rahul Chikatimalla (ORCID: https://orcid.org/0000-0003-2967-1425)
- Tazheen Saleh Muhammad (ORCID: https://orcid.org/0009-0009-5526-3522)
- Himaja Dutt Chigurupati
- Rabia Asim (ORCID: https://orcid.org/0009-0007-3472-3409)
- Bazil Azeem (ORCID: https://orcid.org/0009-0002-5284-876X)
- Laiba Khurram (ORCID: https://orcid.org/0009-0009-1464-701X)
- Saad Ahmed (ORCID: https://orcid.org/0009-0004-6499-7978)
- Muhammad Abdullah Naveed (ORCID: https://orcid.org/0009-0006-9230-6569)
- Sivaram Neppala (ORCID: https://orcid.org/0009-0008-8182-1260)
- Mata‐e‐Alla Doggar
Institutions
- Creighton University (US)
- University of Miami (US)
- The University of Texas at San Antonio Health Science Center (US)
- East Carolina University (US)
- Shaheed Mohtarma Benazir Bhutto Medical University (PK)
- Dow University of Health Sciences (PK)
Publication Details
- Journal
- Clinical Cardiology
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1002/clc.70211
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00